Back HIV Prevention Pre-exposure (PrEP)

Pre-exposure Prophylaxis (PrEP)

U.K.'s Largest Sexual Health Clinic Saw 40% Drop in New HIV Diagnoses in 2016

The clinic at 56 Dean Street in Soho, central London, the largest sexual health clinic in the U.K., saw an unprecedented 40% drop in new HIV diagnoses this year. Another clinic, the Mortimer Market Centre a mile away from Dean Street, has seen an even bigger 50% fall.

alt

Read more:

First Large Study of Long-Acting Injectable for HIV Prevention Now Underway

The National Institutes of Health and industry collaborators last week launched a large-scale clinical trial to test long-acting injectable cabotegravir for HIV prevention. Study HPTN 083 will compare cabotegravir injections administered every 8 weeks versus once-daily oral tenofovir/emtricitabine (Truvada) pre-exposure prophylaxis (PrEP). Results are expected in 2021.

alt

Read more:

HIVR4P 2016: The Long Tail Problem -- Injectable PrEP Trial To Be Extended Due to Drug Persistence

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of people who were given the experimental injectable drug cabotegravir as HIV pre-exposure prophylaxis (PrEP), the drug was still measurable in their body a full year after their last injection.

alt

Read more:

4. PrEP Use Widens, But Disparities Remain

Pre-exposure prophylaxis (PrEP) was again a major HIV story in 2016. The latest figures from a pharmacy survey by Gilead Sciences showed that more than 79,000 people in the U.S. have started Truvada (tenofovir/emtricitabine) for HIV prevention, but the survey does not include all PrEP providers and most experts think this estimate is low.

alt

Read more:

IDWeek 2016: HIV+ Men and Men on PrEP in Boston See Large Increase in Sexually Transmitted Infections

Rates of gonorrhea, syphilis, and chlamydia have risen steeply at Fenway Health in Boston since 2011, according to presentation last week at IDWeek in New Orleans. Being HIV-positive and using pre-exposure prophylaxis (PrEP) to prevent HIV were associated with higher risk of getting-sexually transmitted infections (STIs), but more frequent STI testing and treatment could potentially help reduce the numbers.

alt

Read more: